Genentech Breaks Ground on $750M Manufacturing Expansion in Hillsboro

Genentech, a subsidiary of Swiss drugmaker Roche Group, has broken ground on a $750 million expansion of its manufacturing facility in Hillsboro, Oregon.

The move advances plans announced in August to increase capacity for advanced drug delivery devices and to strengthen the company’s United States manufacturing capabilities. The event marks the start of construction for the 211,000-square-foot expansion, doubling the size of the existing site. Commercial operations are planned to begin in 2031.

The expansion will create approximately 250 manufacturing jobs. Genentech established its Hillsboro campus in 2006. Today, the 75-acre campus is an important part of the company’s manufacturing network, with capabilities spanning drug product manufacturing, packaging, distribution and individualized therapies.

“As construction begins we are one step closer to bringing device fill-finish manufacturing to Hillsboro, strengthening our domestic supply chain and investing in the people and infrastructure that will help us deliver the medicines of the future,” said Genentech CEO Ashley Magargee.

Connect

Inside The Story

Genentech

About Jasmine Kilman

Jasmine Kilman is Content Director of Connect Commercial Real Estate, covering Chicago and greater Chicagoland, the Midwest, Seattle, and the Pacific Northwest. She covers industry trends, transaction deals, market research, and produces daily news stories. With experience in marketing and communications for academic nonprofits and corporate clients, including Hearst Media, Hilton, and Coldwell Banker, Kilman has written about commercial real estate, environmental, social, and corporate governance (ESG), technology, healthcare, and philanthropy. She was born and raised in California and graduated with a degree in public relations. In her spare time, Kilman enjoys hiking and traveling to new locations with her family.

Order Reprints